Oncogenic mutations in KRAS are found in about 25% of lung adenocarcinomas, however many tumors with mutations in KRAS are no longer “dependent” on K-ras for survival, thus targeting these tumors will depend on understanding the molecular underpinnings of K-ras dependence [3, 4]. The gene discussed is KRAS; the disease is lung adenocarcinoma.